What is Fingolimod?
Category: Prescription Drugs
Most popular types: Gilenya
Fingolimod is used to treat relapsing forms of multiple sclerosis (MS) by decreasing the number of MS relapses, or periods of time with worsening of symptoms.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 5059 | 681 | |
| Fever/chills | 3 | 0 | |
| Participate in clinical trial | 3 | 4 | |
| Amyotrophic lateral sclerosis | 1 | 1 | |
| Balance problems | 1 | 1 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 99 | |
| Moderate | 68 | |
| Mild | 135 | |
| None | 394 |
Commonly reported side effects and conditions associated with Fingolimod
| Side effect | Patients | Percentage |
|---|---|---|
| Headaches | 26 | |
| Fatigue | 25 | |
| Elevated liver enzymes | 14 | |
| Nausea | 14 | |
| Heart rate low (bradycardia) | 12 | |
| Hair loss | 11 |
Why patients stopped taking Fingolimod
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 118 | |
| Doctor's advice | 102 | |
| Did not seem to work | 94 | |
| Other | 65 | |
| Personal research | 13 | |
| Expense | 9 | |
| Change in health plan coverage | 5 | |
| Course of treatment ended | 4 |
Duration
Stopped taking Fingolimod
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 34 | |
| 1 - 6 months | 62 | |
| 6 months - 1 year | 55 | |
| 1 - 2 years | 61 | |
| 2 - 5 years | 50 | |
| 5 - 10 years | 10 |
What people switch to and from
Patients started taking Fingolimod after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 80 | |
| Natalizumab (Tysabri) | 59 | |
| Interferon beta-1a SubQ injection (Rebif) | 48 | |
| Interferon beta-1a IM Injection (Avonex) | 45 | |
| Dimethyl fumarate (Tecfidera) | 39 |
Patients stopped taking Fingolimod and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Natalizumab (Tysabri) | 38 | |
| Dimethyl fumarate (Tecfidera) | 31 | |
| Ocrelizumab (Ocrevus) | 26 | |
| Teriflunomide (Aubagio) | 18 | |
| Glatiramer acetate (Copaxone) | 11 |
Last updated: